Higher leukocyte nadirs with lithium carbonate after chemotherapy.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007958:Leukocyte Count; D008094:Lithium / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D009447:Neuroblastoma / Q000188:drug therapy; D010208:Papaverine / Q000627:therapeutic use; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012512:Sarcoma, Ewing / Q000188:drug therapy; D013724:Teratoma / Q000188:drug therapy; D014271:Trifluridine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use; D009396:Wilms Tumor / Q000188:drug therapy
D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D008094:Lithium; D010208:Papaverine; D014271:Trifluridine; D006918:Hydroxyurea